Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

AVB‐S6‐500 neutralized growth arrest‐specific 6 (GAS6) protein and effectively inhibited AXL signaling in preclinical cancer models. A target‐mediated drug disposition (TMDD) pharmacokinetic/pharmacodynamic (PK/PD) model was used to select first‐in‐human (FIH) doses for AVB‐S6‐500 based on predicted...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifacio, Laura, Dodds, Michael, Prohaska, David, Moss, Aaron, Giaccia, Amato, Tabibiazar, Ray, McIntyre, Gail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951457/
https://www.ncbi.nlm.nih.gov/pubmed/31599479
http://dx.doi.org/10.1111/cts.12706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951457/
https://www.ncbi.nlm.nih.gov/pubmed/31599479
http://dx.doi.org/10.1111/cts.12706

Ejemplares similares